The Question No One Wants to Ask Aloud
“Are small pharma companies bad?”
Why?
Because the moment a drug recall or manufacturing issue hits the headlines, the instinctive reaction is:
“It must be a small pharma company.”
This stereotype has grown so powerful that many automatically equate “small” with “unsafe”, “unprofessional”, or “non-compliant.”
But is this stigma justified?
Or have we as an industry overlooked the complex realities, the economic struggles, the regulatory burdens, and the systemic pressure placed on India’s thousands of small and medium-scale pharmaceutical manufacturers?
This article dives deep into the truth — not the sugar-coated version, but the actual on-ground reality.
We explore the role of small pharma, their challenges, the impact of the revised Schedule M, and the difference between those who are struggling and those who are truly negligent.
1. India’s Pharmaceutical Backbone: A Giant Built on Small Foundations
India is proudly known as “The Pharmacy of the World.”
A global leader in generic medicines.
A lifeline for more than 200 countries.
Yet behind this global title lies an overlooked truth:
India has over 10,500 pharmaceutical manufacturing units — and nearly 70% are small or medium-scale.
These SMEs:
Are family-owned
Operate with lean teams
Run with limited budgets
Supply affordable medicines across India
They manufacture the everyday generics used by millions:
Paracetamol
Antibiotics
Antacids
Cough syrups
Pediatric formulations
Essential tablets and capsules
They ensure that a ₹2 strip in a city is still ₹2 in a rural clinic.
Small pharma is not the fringe — it is the foundation.
Yet it carries the worst perception.
2. The Stigma: Why Small Pharma Is Often Blamed
Let’s acknowledge the stereotype:
“Small pharma units are unsafe.”
“Small companies don’t follow GMP.”
“Small units cut corners.”
These statements are repeated often — but rarely questioned.
Why?
Because the public sees outcomes, not the circumstances.
They see deviations, not the pressures that caused them.
They see a failed batch, not the economic hardship behind it.
Small pharma is blamed because:
Their facilities are modest
Their infrastructure is aging
Their staff strength is limited
Their documentation systems are still evolving
But their intent is often far better than perceived.
Most small units are not negligent — they are overburdened, underfunded, and trying to stay afloat.
3. The Harsh Economic Reality: Compliance vs. Survival
The economic challenges faced by small pharma are enormous.
3.1 DPCO Controls: Price vs. Quality
Many essential medicines fall under DPCO.
The manufacturer’s margin may be:
₹0.50 to ₹1 per strip
Sometimes even less
This leaves little room for:
Upgrades
Modernization
Hiring skilled manpower
Investing in documentation systems
Funding training programs
3.2 Raw Material Price Volatility
API and excipient costs change frequently.
Contracts are often fixed.
Losses accumulate silently.
3.3 High Utility Costs
Running HVAC, purified water systems, AHUs, and QC equipment can cost lakhs monthly.
3.4 Manpower Attrition
Trained staff often move to bigger companies for better salaries.
Small pharma must constantly train new employees.
3.5 Continuous Audits
Buyer audits, loan-license audits, and regulatory inspections lead to:
Downtime
Documentation load
Corrective action expenditure
Small pharma isn’t choosing shortcuts.
Small pharma is fighting for survival.
4. Revised Schedule M: The Biggest Regulatory Shift in Two Decades
The revised Schedule M is essential — no doubt.
It raises the bar for quality across India.
But it also creates major challenges for small units.
Upgrading to Revised Schedule M costs ₹2–5 crore, depending on:
HVAC zoning
Area classification
AHU upgrades
Cleanroom paneling
Epoxy flooring
Water system qualification
Modern QMS adoption
Equipment qualification
Updated validations
New utilities and electrical layouts
This expense is impossible for many small units without support.
So when a regulator asks:
“Why haven’t you upgraded yet?”
The honest answer is:
They want to — but they cannot afford to.
Not immediately.
Not without assistance.
🎥 Mid-Article Deep-Dive — Watch the Full Explainer
The video covers this entire section with visuals and real-world examples.
👉 WATCH THE FULL VIDEO HERE
5. Regulatory Pressure: Fear Over Guidance
Small pharma units don’t fear quality.
They fear:
unpredictable interpretations
inconsistent inspection styles
heavily documentation-focused audits
subjective expectations
One inspector may focus on HVAC.
Another on documentation accuracy.
Another on change control.
Another on trend analysis.
Another on batch record formats.
This inconsistency has created inspection anxiety, not quality culture.
Audits should inspire improvement — not fear.
6. Big Pharma’s Silent Shadow
Here’s the irony:
Small units often manufacture products for big companies under contract.
When everything goes right:
The big company gets the credit.
When something goes wrong:
The manufacturer gets the blame.
Big companies have:
Stronger PR teams
Larger legal teams
More influence
Better negotiation power
Greater market presence
Small pharma doesn’t.
Yet they often produce the same products under the strict SOPs of those large corporations.
7. The Unwilling Few — The Real Problem
It would be unfair to claim all small pharma units are victims.
Some are truly negligent.
These are the ones who:
ignore documentation
skip calibrations
reuse old batch records
avoid validations
maintain poor housekeeping
depend on shortcuts
These few create a negative image for everyone else.
They must be corrected, penalized, or shut down.
But they represent a small minority.
8. The Real Solution: A Graded Compliance Model
India needs a maturity model to categorize units based on their readiness and intent:
Category A — Fully Compliant
Encourage exports and expansions.
Category B — Substantially Compliant
Provide incentives for upgrades.
Category C — Non-Compliant but Willing
Offer training, mentoring, and technical support.
Category D — Persistently Unwilling
Take strict regulatory action.
This creates:
fairness
structure
opportunity
accountability
9. The Path Forward: What India MUST Do
India’s small pharma will thrive if supported through:
✔ Subsidies for modernization
✔ Soft loans for facility upgrades
✔ Digital QMS tools at affordable cost
✔ GMP Support Cells in every state
✔ Training and mentoring programs
✔ Shared QC labs in pharma clusters
✔ Recognizing improved companies
✔ Uniform interpretation of Schedule M
Support → Compliance → Better public health.
10. The Final Truth: Are Small Pharma Companies Bad?
So… are small pharma companies bad?
No.
Not even close.
Small pharma companies are:
the backbone of affordable healthcare
the first line of medicine supply in India
dedicated, hardworking, and essential
victims of financial and regulatory pressure
trying to maintain quality with limited resources
But yes — a small group of companies remains negligent.
They should be corrected.
Or shut down.
However, they do not represent the majority.
The majority deserve support, guidance, and recognition — not stigma.
11. A Future We Can Build — Together
Imagine an India where:
every small manufacturer meets WHO-GMP
modernization doesn’t mean closure
audits help instead of scare
documentation becomes digital and accessible
skilled manpower stays because the ecosystem supports them
state-level GMP support centres mentor SMEs
quality is a culture, not a compliance burden
This future is possible.
It is within reach.
And it depends on how we treat small pharma today.
12. A Message for Every Reader
If you’ve reached this point, you’re someone who cares about:
patient safety
industry fairness
regulatory balance
quality culture
So remember this:
Quality isn't built by fear.
Compliance isn’t strengthened by intimidation.
Industries don’t grow when we punish the willing.
They grow when we uplift them.
🎥 Watch the Full Video — The Story Hits Harder Visually
The written article gives clarity.
The video gives emotion, visuals, and narrative depth.
👉 CLICK HERE TO WATCH THE COMPLETE VIDEO
💬 What do YOU think is the biggest challenge for small pharma today?
Comment on the YouTube video — your insight could help thousands.
If you found this article valuable:
✔ Share it in WhatsApp pharma groups
✔ Share it with QA/QC teams
✔ Share it with small pharma owners
✔ Share it with regulatory professionals
✔ Share it with your LinkedIn network
